Effect of mifepristone on inhibition of ovulation and induction of luteolysis

I. M. Spitz, H. B. Croxatto, P. Lähteenmäki, O. Heikinheimo, C. W. Bardin

Resultado de la investigación: Article

13 Citas (Scopus)

Resumen

Mifepristone administration to women in the mid- or late follicular phase delays the luteinizing hormone (LH) surge and prolongs the follicular phase. Since the resumption of follicular growth commences following mifepristone cessation, the drug must be given either continuously or at repeated intervals in order to block ovulation. Using various regimens with or without exogenous progestins, ovulation was inhibited in the majority of subjects. However, this was not consistent and in several instances, LH surges and a rise in plasma progesterone were suggestive of ovulation and corpus luteum function. Therefore, mifepristone cannot be used as a contraceptive which will reliably inhibit ovulation. With low- dose mifepristone administration, alterations in endometrial morphology were characterized by a delay in maturation despite the presence of ovulation. This suggests that the endometrium displays a greater sensitivity to mifepristone than does the pituitary, a finding that may have important contraceptive implications. Late luteal- phase mifepristone administration to women who were not sexually active did not alter their menstrual rhythm, bleeding patterns or steroid and gonadotrophin concentrations. However, when used in unprotected women in the late luteal phase, mifepristone did not uniformly terminate all pregnancies. On the other hand, when used within 72 h of intercourse, mifepristone was as effective a post-coital agent as the standard high- dose oestrogen-progestin combination.

Idioma originalEnglish
Páginas (desde-hasta)69-76
Número de páginas8
PublicaciónHuman Reproduction
Volumen9
DOI
EstadoPublished - 1 ene 1994

Huella dactilar

Luteolysis
Mifepristone
Ovulation Induction
Ovulation
Follicular Phase
Luteal Phase
Progestins
Luteinizing Hormone
Contraceptive Agents
Corpus Luteum
Endometrium
Gonadotropins
Progesterone
Estrogens
Steroids
Hemorrhage
Pregnancy

ASJC Scopus subject areas

  • Rehabilitation
  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Developmental Biology
  • Physiology

Citar esto

Spitz, I. M. ; Croxatto, H. B. ; Lähteenmäki, P. ; Heikinheimo, O. ; Bardin, C. W. / Effect of mifepristone on inhibition of ovulation and induction of luteolysis. En: Human Reproduction. 1994 ; Vol. 9. pp. 69-76.
@article{d2c5fcefb8f74fdd806fdcae90b87e1a,
title = "Effect of mifepristone on inhibition of ovulation and induction of luteolysis",
abstract = "Mifepristone administration to women in the mid- or late follicular phase delays the luteinizing hormone (LH) surge and prolongs the follicular phase. Since the resumption of follicular growth commences following mifepristone cessation, the drug must be given either continuously or at repeated intervals in order to block ovulation. Using various regimens with or without exogenous progestins, ovulation was inhibited in the majority of subjects. However, this was not consistent and in several instances, LH surges and a rise in plasma progesterone were suggestive of ovulation and corpus luteum function. Therefore, mifepristone cannot be used as a contraceptive which will reliably inhibit ovulation. With low- dose mifepristone administration, alterations in endometrial morphology were characterized by a delay in maturation despite the presence of ovulation. This suggests that the endometrium displays a greater sensitivity to mifepristone than does the pituitary, a finding that may have important contraceptive implications. Late luteal- phase mifepristone administration to women who were not sexually active did not alter their menstrual rhythm, bleeding patterns or steroid and gonadotrophin concentrations. However, when used in unprotected women in the late luteal phase, mifepristone did not uniformly terminate all pregnancies. On the other hand, when used within 72 h of intercourse, mifepristone was as effective a post-coital agent as the standard high- dose oestrogen-progestin combination.",
keywords = "Gonadotrophins, Luteolysis, Mifepristone, Ovulation Inhibition, RU486",
author = "Spitz, {I. M.} and Croxatto, {H. B.} and P. L{\"a}hteenm{\"a}ki and O. Heikinheimo and Bardin, {C. W.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1093/humrep/9.suppl_1.69",
language = "English",
volume = "9",
pages = "69--76",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",

}

Effect of mifepristone on inhibition of ovulation and induction of luteolysis. / Spitz, I. M.; Croxatto, H. B.; Lähteenmäki, P.; Heikinheimo, O.; Bardin, C. W.

En: Human Reproduction, Vol. 9, 01.01.1994, p. 69-76.

Resultado de la investigación: Article

TY - JOUR

T1 - Effect of mifepristone on inhibition of ovulation and induction of luteolysis

AU - Spitz, I. M.

AU - Croxatto, H. B.

AU - Lähteenmäki, P.

AU - Heikinheimo, O.

AU - Bardin, C. W.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Mifepristone administration to women in the mid- or late follicular phase delays the luteinizing hormone (LH) surge and prolongs the follicular phase. Since the resumption of follicular growth commences following mifepristone cessation, the drug must be given either continuously or at repeated intervals in order to block ovulation. Using various regimens with or without exogenous progestins, ovulation was inhibited in the majority of subjects. However, this was not consistent and in several instances, LH surges and a rise in plasma progesterone were suggestive of ovulation and corpus luteum function. Therefore, mifepristone cannot be used as a contraceptive which will reliably inhibit ovulation. With low- dose mifepristone administration, alterations in endometrial morphology were characterized by a delay in maturation despite the presence of ovulation. This suggests that the endometrium displays a greater sensitivity to mifepristone than does the pituitary, a finding that may have important contraceptive implications. Late luteal- phase mifepristone administration to women who were not sexually active did not alter their menstrual rhythm, bleeding patterns or steroid and gonadotrophin concentrations. However, when used in unprotected women in the late luteal phase, mifepristone did not uniformly terminate all pregnancies. On the other hand, when used within 72 h of intercourse, mifepristone was as effective a post-coital agent as the standard high- dose oestrogen-progestin combination.

AB - Mifepristone administration to women in the mid- or late follicular phase delays the luteinizing hormone (LH) surge and prolongs the follicular phase. Since the resumption of follicular growth commences following mifepristone cessation, the drug must be given either continuously or at repeated intervals in order to block ovulation. Using various regimens with or without exogenous progestins, ovulation was inhibited in the majority of subjects. However, this was not consistent and in several instances, LH surges and a rise in plasma progesterone were suggestive of ovulation and corpus luteum function. Therefore, mifepristone cannot be used as a contraceptive which will reliably inhibit ovulation. With low- dose mifepristone administration, alterations in endometrial morphology were characterized by a delay in maturation despite the presence of ovulation. This suggests that the endometrium displays a greater sensitivity to mifepristone than does the pituitary, a finding that may have important contraceptive implications. Late luteal- phase mifepristone administration to women who were not sexually active did not alter their menstrual rhythm, bleeding patterns or steroid and gonadotrophin concentrations. However, when used in unprotected women in the late luteal phase, mifepristone did not uniformly terminate all pregnancies. On the other hand, when used within 72 h of intercourse, mifepristone was as effective a post-coital agent as the standard high- dose oestrogen-progestin combination.

KW - Gonadotrophins

KW - Luteolysis

KW - Mifepristone

KW - Ovulation Inhibition

KW - RU486

UR - http://www.scopus.com/inward/record.url?scp=0028335834&partnerID=8YFLogxK

U2 - 10.1093/humrep/9.suppl_1.69

DO - 10.1093/humrep/9.suppl_1.69

M3 - Article

C2 - 7962472

AN - SCOPUS:0028335834

VL - 9

SP - 69

EP - 76

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

ER -